Logo image of CELL

PHENOMEX INC (CELL) Stock Price, Quote, News and Overview

NASDAQ:CELL - Nasdaq - US0843101017 - Common Stock - Currency: USD

0.9981  +0 (+0.31%)

After market: 0.999 +0 (+0.09%)

CELL Quote, Performance and Key Statistics

PHENOMEX INC

NASDAQ:CELL (9/29/2023, 8:22:41 PM)

After market: 0.999 +0 (+0.09%)

0.9981

+0 (+0.31%)

Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryLife Sciences Tools & Services
Statistics
52 Week High1.27
52 Week Low0.38
Market Cap98.79M
Shares98.98M
Float87.41M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)11-06 2023-11-06/amc
IPO07-17 2020-07-17


CELL short term performance overview.The bars show the price performance of CELL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60 80 100

CELL long term performance overview.The bars show the price performance of CELL in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of CELL is 0.9981 USD. In the past month the price increased by 5.06%.

PHENOMEX INC / CELL Daily stock chart

CELL Latest News, Press Releases and Analysis

News Image
a year ago - PhenomeX

PhenomeX Announces Opto® Memory B Discovery Human Workflow on the Beacon® Optofluidic Platform

/PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), a functional cell biology company, announced the Opto® Memory B Discovery Human workflow, further expanding...

News Image
a year ago - PhenomeX

PhenomeX Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development Workflows

/PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), a functional cell biology company, is pleased to announce that GSK will present data on the SpotLightâ„¢ Human...

News Image
a year ago - PhenomeX

PhenomeX to Participate in Upcoming Cell Biology Conferences

/PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), a functional cell biology company, today announced it will showcase their latest optofluidic and proteomic...

News Image
a year ago - PhenomeX

PhenomeX Unveils Meteorâ„¢ Chips For Quantitative Bulk Analysis On The IsoSparkâ„¢ Platform To Revolutionize High Throughput Multiplexed Hands-Free Proteomics

/PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), the functional cell biology company, today announced the launch of Meteorâ„¢ chips on the IsoSparkâ„¢ platform,...

News Image
a year ago - Halper Sadeh LLP

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SOVO, THRN, ABCM, CELL

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

CELL Competitors/Peers

The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
TMO THERMO FISHER SCIENTIFIC INC 27.34 228.64B
DHR DANAHER CORP 29.74 160.88B
A AGILENT TECHNOLOGIES INC 28.64 43.21B
IQV IQVIA HOLDINGS INC 18.54 36.55B
MTD METTLER-TOLEDO INTERNATIONAL 35.77 28.79B
WST WEST PHARMACEUTICAL SERVICES 50.53 24.74B
WAT WATERS CORP 36.48 24.67B
ILMN ILLUMINA INC 76.73 21.05B
ICLR ICON PLC 14.19 16.44B
RVTY REVVITY INC 26.67 15.35B
AVTR AVANTOR INC 22.73 15.16B
TECH BIO-TECHNE CORP 41.09 11.69B

About CELL

Company Profile

CELL logo image PhenomeX, Inc. is a biology company that engages in the study of cells. The company is headquartered in Emeryville, California and currently employs 285 full-time employees. The company went IPO on 2020-07-17. The firm enables scientists to leverage each cell and drive the next generation of functional cell biology that will advance human health. The firm enables scientists to reveal insights into cell function and obtain a full view of the behavior of each cell. Its specific suite of proven tools and services offers unparalleled resolution and speed the insights that are key to advancing discoveries that can completely improve the prevention and treatment of disease. The Company’s platforms are used by researchers across the globe, including various global pharmaceutical companies and approximately 85% of United States cancer centers.

Company Info

PHENOMEX INC

5858 Horton Street, Suite 320

Emeryville CALIFORNIA US

Employees: 285

Company Website: https://www.phenomenex.com/

Phone: 15108582855.0

CELL FAQ

What is the stock price of CELL?

The current stock price of CELL is 0.9981 USD.


What is the symbol for PHENOMEX INC stock?

The exchange symbol of PHENOMEX INC is CELL and it is listed on the Nasdaq exchange.


On which exchange is CELL stock listed?

CELL stock is listed on the Nasdaq exchange.


Is CELL a good stock to buy?

Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for CELL, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of CELL.


Does CELL stock pay dividends?

CELL does not pay a dividend.


When does CELL stock report earnings?

CELL will report earnings on 2023-11-06, after the market close.


What is the Price/Earnings (PE) ratio of CELL?

CELL does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.38).


CELL Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to CELL.


Chartmill TA Rating
Chartmill Setup Rating

CELL Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to CELL. While CELL seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CELL Financial Highlights

Over the last trailing twelve months CELL reported a non-GAAP Earnings per Share(EPS) of -1.38. The EPS increased by -9.52% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -69.85%
ROE -111.9%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%10.53%
Sales Q2Q%-26.58%
EPS 1Y (TTM)-9.52%
Revenue 1Y (TTM)-17.32%

CELL Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 51% to CELL. The Buy consensus is the average rating of analysts ratings from 11 analysts.

For the next year, analysts expect an EPS growth of 17.97% and a revenue growth -10.41% for CELL


Ownership
Inst OwnersN/A
Ins Owners0.13%
Short Float %N/A
Short RatioN/A
Analysts
Analysts50.91
Price Target1.53 (53.29%)
EPS Next Y17.97%
Revenue Next Year-10.41%